NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $58.13 -2.60 (-4.28%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$58.80 +0.67 (+1.16%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARWR alerts:Sign Up Key Stats Today's Range$58.08▼$60.7350-Day Range$58.13▼$89.4152-Week Range$34.61▼$95.49Volume2.26 million shsAverage Volume2.43 million shsMarket Capitalization$8.19 billionP/E RatioN/ADividend YieldN/APrice Target$98.31Consensus RatingModerate Buy Company Overview Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins. The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs. Its pipeline has included investigational treatments for cardiometabolic disorders, liver diseases, pulmonary conditions and other serious illnesses. Programs have targeted conditions such as hypertriglyceridemia and dyslipidemia, alpha-1 antitrypsin deficiency-associated liver disease, and respiratory diseases. Founded in 2003 and headquartered in Pasadena, California, Arrowhead conducts research and clinical development activities through its own operations and collaborations with pharmaceutical companies. The company serves global markets through international clinical programs and licensing or development partnerships. Arrowhead is led by Christopher Anzalone, Ph.D., who has served as its president and chief executive officer since 2008.AI Generated. May Contain Errors. Read More Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreARWR MarketRank™: 2.483802723785 of 5 starsArrowhead Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 551st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 10 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArrowhead Pharmaceuticals has a consensus price target of $98.31, representing about 69.1% upside from its current price of $58.13.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($3.62) to ($4.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -25.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -25.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 15.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.92% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.03.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 16.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.28 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arrowhead Pharmaceuticals this week, compared to 8 articles on an average week.Search Interest6 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows8 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,186,600.00 in company stock.Percentage Held by Insiders3.60% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARWR Stock News HeadlinesHead-To-Head Comparison: Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus DBV Technologies (NASDAQ:DBVT)36 minutes ago | americanbankingnews.comAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Humana (HUM) and Arrowhead Pharmaceuticals (ARWR)October 13 at 1:57 PM | theglobeandmail.comElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11. | Brownstone Research (Ad)Arrowhead’s Plozasiran Trial Completion Signals a Pivotal Moment for ARWR InvestorsOctober 9, 2026 | tipranks.comArrowhead’s Plozasiran Hits Phase 3 Completion: What Investors Should Watch NextOctober 8, 2026 | tipranks.comArrowhead Pharmaceuticals, Inc. (ARWR)October 7, 2026 | finance.yahoo.comArrowhead Flat on FDA NodOctober 7, 2026 | baystreet.caArrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe HypertriglyceridemiaOctober 7, 2026 | marketscreener.comMSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $66.39 at the beginning of 2026. Since then, ARWR stock has decreased by 12.4% and is now trading at $58.13. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.13. Arrowhead Pharmaceuticals's quarterly revenue was up 171.0% on a year-over-year basis. Read the conference call transcript. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional shareholders of Arrowhead Pharmaceuticals include Sax Wealth Advisors LLC (0.01%), Financial Enhancement Group LLC and GAMMA Investing LLC. Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Daniel Joseph Apel, Martin Javier San, Douglas B Given, Tracie Oliver, Michael S Perry, Mauro Ferrari, William D Waddill, Hongbo Lu, Victoria Vakiener and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and AbbVie (ABBV). Company Calendar Last Earnings8/04/2026Today10/13/2026Study update10/14/2026Next Earnings (Estimated)11/24/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 9 days, ARWR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARWR CIK879407 Webwww.arrowheadpharma.com Phone(626) 696-4702Fax626-304-3401Employees711Year Founded2001Price Target and Rating Average Price Target for Arrowhead Pharmaceuticals$98.31 High Price Target$126.00 Low Price Target$46.00 Potential Upside/Downside+69.1%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.63 million Net Margins-47.79% Pretax Margin-37.65% Return on Equity-60.06% Return on Assets-17.37% Debt Debt-to-Equity Ratio1.77 Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$829.45 million Price / Sales9.87 Cash Flow$0.11 per share Price / Cash Flow508.62 Book Value$3.64 per share Price / Book15.97Miscellaneous Outstanding Shares140,860,000Free Float135,786,000Market Cap$8.19 billion OptionableOptionable Beta1.29 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ARWR) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARWR Stock Alerts